BioSpace News Archive

Antibe Therapeutics Inc. has filed its financial and operating results for the fiscal quarter ended September 30, 2021.

Metagenomi today announced that the company will give three presentations at the CRISPR 2.0 conference, occurring virtually November 16–18.

VistaGen Therapeutics, Inc today announced that Shawn Singh, Chief Executive Officer, will participate in a fireside chat at Jefferies London Healthcare Conference

Royal Philips, a global leader in health technology, announced it has received 510 clearance from the U.S. Food and Drug Administration for its new Liver Fat Quantification tools as part of the latest release of its ultrasound systems EPIQ Elite and Affiniti, bringing the cost and accessibility advantages of sonography to the diagnosis of early-stage liver disease.

Biofrontera Inc., a biopharmaceutical company specializing in the commercialization of dermatological products, announced the start of a clinical study program focused on optimizing and expanding the market positioning of its in-licensed FDA-approved prescription drug Ameluz® for photodynamic therapy in the United States.

Advantis Medical Imaging, a pioneering manufacturer of cloud-based medical imaging software solutions, today announced its first 510(k) clearance from the U.S. Food and Drug Administration (FDA).

Individualized cancer diagnosis and treatment regimens are the future of oncology care and require harnessing the advances of scientific research.

Cellares Corporation, a life sciences technology company pioneering a revolutionary automated approach to cell therapy manufacturing, today announced the appointment of Ezekiel J. Emanuel, MD, PhD, to its Board of Advisors.

Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products.

Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission (EC) has granted marketing authorization for VUMERITY® (diroximel fumarate) to treat adults with relapsing-remitting multiple sclerosis (MS).